GLP-1SM Research Compound

GLP-1SM exerts its effects through several interconnected mechanisms:

1. GLP-1 Receptor Activation: GLP-1SM binds to and activates GLP-1 receptors, which are expressed in various tissues including pancreatic islets, the gastrointestinal tract, and the central nervous system. This activation initiates intracellular signaling cascades, primarily through cyclic AMP (cAMP) and protein kinase A (PKA) pathways.

2. Pancreatic Effects: In pancreatic β-cells, GLP-1SM enhances glucose-stimulated insulin secretion by increasing intracellular cAMP levels and promoting calcium influx. Simultaneously, it inhibits glucagon secretion from α-cells; both actions have been examined in studies of glucose homeostasis.

3. Central Nervous System Effects: GLP-1SM crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus and brainstem.

4. Gastrointestinal Effects: GLP-1SM slows gastric emptying, an effect examined in relation to postprandial glucose excursions and the sensation of fullness.

5. Cardiovascular System: While the exact mechanisms are not fully elucidated, GLP-1SM appears to have direct and indirect effects on the cardiovascular system. Endpoints examined include endothelial function, inflammatory markers, and lipid metabolism.

6. Metabolic Rate: Some studies suggest that GLP-1SM may influence energy expenditure, potentially through effects on brown adipose tissue activation, although this area requires further investigation.

Published studies have measured endpoints relating to glycemic control, body weight and cardiovascular markers. The complex interplay of these effects underscores the importance of continued research to fully elucidate the research relevance and physiological impacts of GLP-1SM and other GLP-1 receptor agonists.

• Glucose Homeostasis: GLP-1SM stimulates glucose-dependent insulin secretion from pancreatic β-cells while suppressing glucagon release from α-cells. This dual action has been examined in islet and cell-based assays and in preclinical models of glucose homeostasis.

• Cardiovascular Effects: Research has examined GLP-1 receptor signalling in relation to cardiovascular parameters, including lipid handling and blood pressure regulation, in preclinical models.

Handle as a laboratory research chemical of unknown hazard. Use gloves and eye protection, avoid inhalation of the lyophilized powder, and follow standard laboratory handling procedures.

Reconstitute and store according to the product label. Lyophilized material should be kept cool, dry and protected from light; reconstituted material should be held at 2-8°C and protected from light.

The safety profile of GLP-1SM has not been established. This compound is supplied for laboratory research use only and is not approved for human or veterinary use.

GLP-1SM is a GLP-1 receptor agonist research compound used to investigate the roles of GLP-1 receptor signalling in metabolic and cardiovascular physiology. Published in-vitro and preclinical studies have examined its effects on receptor activation, insulin and glucagon secretion, gastric emptying and energy balance, making it a subject of ongoing study of GLP-1 receptor signalling in in-vitro and preclinical models. As investigations continue, GLP-1SM may provide further insight into incretin receptor pharmacology.